4-aminoisoindoline-1,3-dione compounds for DLBCL treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies for Diffuse Large B-Cell Lymphoma (DLBCL) are inadequate due to significant side effects and drug resistance, necessitating a safer and more effective treatment option.
Innovation Solution
Development of 4-aminoisoindoline-1,3-dione compounds for use in pharmaceutical compositions that can be administered to treat or prevent DLBCL, offering an alternative to conventional chemotherapy and radiation therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy agents are used to treat DLBCL, then cancer cell growth inhibition is achieved, but significant toxic side effects and multidrug resistance occur
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of isoindoline-1,3-dione compounds through various substitutions (R1-R6 groups including alkyl, aryl, heteroaryl, and their combinations) to optimize therapeutic efficacy while reducing toxicity. The compounds are designed with specific molecular weight ranges (150-500 Da) and structural features that enhance selective inhibition of cancer cell growth compared to conventional chemotherapeutics
Solution Approach 2:
The invention creates composite chemical structures by combining isoindoline-1,3-dione core with diverse substituent groups (aryl, heteroaryl, alkyl, and their combinations) to produce compounds with enhanced pharmacological properties. This composite approach allows tuning of biological activity, selectivity, and reduced off-target effects compared to single-structure chemotherapeutic agents
2Reliability
If radiation therapy is applied to treat DLBCL, then tumor control is achieved, but serious side effects and limited effectiveness occur
Solution Approach 1:
The patent replaces the physical mechanism of radiation therapy with a chemical mechanism using isoindoline-1,3-dione compounds that selectively inhibit cancer cell growth through molecular interaction with cellular targets. This chemical approach avoids the ionizing radiation damage to normal tissues while maintaining anti-tumor efficacy through selective cytotoxicity against DLBCL cells
3Quantity of substance
If surgery is performed to remove neoplastic tissue, then cancer mass reduction is achieved, but complete removal is not possible and patient health constraints apply
Solution Approach 1:
The invention extracts and targets the metabolic and proliferative pathways specific to DLBCL cells using isoindoline-1,3-dione compounds. The compounds selectively interfere with cancer cell survival mechanisms while sparing normal cells, effectively removing the cancerous component without the physical constraints and risks of surgical intervention
Data Source
AI summary
Provided herein are 4-aminoisoindoline-1,3-dione compounds having the following structure:wherein R, Ring A, and n are as defined herein, compositions comprising an effective amount of a 4-aminoisoindoline-1,3-dione compound, and methods for treating or preventing disorders.